EUCTR2009-010887-41-FR进行中（未招募）1 期
A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combination with ritonavir-boosted atazanavir (ATV/rtv) and 1 NRTI in treatment-experienced HIV-1 infected subjects
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects, aged 18 years or above.
- •2. Subject has signed the informed consent form (ICF) voluntarily.
- •3. Subject can comply with the protocol requirements.
- •4. Subject with documented HIV-1 infection.
- •5. HIV-1 plasma viral load at Screening Visit above 500 HIV-1 RNA copies/mL.
- •6. Subject has received at least one HAART regimen
- •Note: HAART is defined as potent anti-HIV treatment usually including a combination
- •of 3 or more drugs with activity against HIV whose purpose is to reduce viral load to
- •undetectable. This regimen usually includes treatment with at least 2 NRTIs in
- •combination with at least 1 additional ARV from the NNRTI and/or PI class.
- •Note: Subjects on a structured treatment interruption for a minimum of 4 weeks at the time of screening are allowed.
- •7. On a stable antiretroviral therapy (ART) for at least 8 weeks at Screening and willing to stay on that treatment until the start of the Pre-Treatment Phase.
- •8. Presence of at least 1 of the following mutations (based upon the following list of
- •47 NNRTI RAMs: V90I, A98G, L100I, K101E/H/P/Q, K103H/N/S/T, V106A/I/M,
- •V108I, E138A/G/K/Q, V179D/E/F/G/I/T, Y181C/I/V, Y188C/H/L, V189I,
- •G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T, Y318F) on the
- •resistance test at Screening or from prior genotypic analysis, evidence of which should be available in the source documents and enrollment of the subject based on these data needs to be agreed upon by the sponsor.
- •9. Demonstrated sensitivity to ATV, ETR and at least one of the selected NRTIs based on the resistance test at Screening.
- •10.General medical condition, in the investigator’s opinion, does not interfere with the assessments and completion of the trial.
- •Subjects who meet all of the criteria above and the following criteria are eligible for the
- •1. Currently enrolled in trial TMC125-C238 for > 24 weeks.
- •2. Informed Consent Form (ICF) signed voluntarily.
- •3. HIV-1 plasma viral load < 50 copies/mL on at least the 2 most recent consecutive visits.
- •4. General medical condition, in the investigator’s opinion, does not interfere with the
- •assessments and completion of the substudy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Primary HIV-1 infection.
- •2. Previously documented HIV-2 infection.
- •3. Previously failed 2 or more HIV PI-containing regimens.
- •4. Use of disallowed concomitant therapy.
- •5. Previous diagnosis of hereditary hyperbilirubinemia (eg. Gilbert’s syndrome, Crigler- Najjar syndrome).
- •6. Any condition (including but not limited to alcohol and drug use) which, in the opinion of the investigator, could compromise the subject’s safety or adherence to the protocol.
- •7. Life expectancy less than 6 months according to the judgment of the investigator.
- •8. Subject has any currently active AIDS defining illness with the following exceptions, which must be discussed with the sponsor prior to enrollment:
- •a. Stable cutaneous Kaposi’s Sarcoma (i.e., no pulmonary or gastrointestinal
- •involvement other than oral lesions) that is unlikely to require any form of
- •systemic therapy during the trial period.
- •b. Wasting syndrome due to HIV infection if, in the investigator’s opinion, it is not
- •actively progressive and its treatment does not require hospitalization or
- •compromise the subject’s safety or compliance to adhere to trial related
- •procedures.
- •Note: An AIDS defining illness not clinically stabilized for at least 30 days will be
- •considered clinically active. Primary and secondary prophylaxis for an AIDS defining
- •illness is allowed in case the medication used is not part of the disallowed medication.
- •9. Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or
- •findings during screening of medical history, laboratory or physical examination that, in the investigator’s opinion, would compromise the subject’s safety or outcome of the trial.
- •10. Acute viral hepatitis including but not limited to A, B, or C.
- •11. Chronic hepatitis B and/or C co-infection.
- •12. Receipt of an investigational drug or investigational vaccine within 30 days prior to the trial drug administration.
- •13. Previously demonstrated clinically significant allergy or hypersensitivity to ETR or to any of the excipients of ETR.
- •14. Pregnant or breastfeeding female subject.
- •15. Female subject of childbearing potential not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational medication;
- •Note: Hormone-based contraception may not be reliable when taking ARV agents;
- •therefore, to be eligible for this trial, women of childbearing potential should either:
- •use a double barrier method to prevent pregnancy (i.e., using a male condom with
- •diaphragm or cervical cap); or
- •use an hormonal contraceptive in combination with a barrier contraceptive (i.e.,
- •female/male condom, diaphragm or cervical cap); or
- •use an intrauterine device (IUD) in combination with a barrier contraceptive (i.e.,
- •female/male condom, diaphragm or cervical cap); or
- •do not engage in heterosexual sex, or have a vasectomized partner with confirmed
- •Note: Women who are postmenopausal for at least 2 years and women with surgical
- •sterilization, i.e., tubal ligation or total hysterectomy, are considered of non-childbearing
- •Note: Spermicides contain non-oxynol-9 and should not be used as this can potentially
- •increase the rate of HIV-1 transmission.
- •Note: Use of an IUD can increase the risk of sexually transmitted infections, including
- •16. Non-vasectomized heterosexually active male subject not using effective birth control methods or no
研究者
相似试验
进行中（未招募）
1 期
Open-label clinical trial with an open-label extension to investigate the safety of BMN 111 in infants and young children with achondroplasiaMedDRA version: 20.0Level: LLTClassification code 10000452Term: AchondroplasiaSystem Organ Class: 100000004850achondroplasiaEUCTR2020-001055-40-GBBioMarin Pharmaceutical Inc.20
已完成
不适用
An open-label, randomized, controlled study of treatment duration of peginterferon alpha-2a monotherapy in patients with chronic hepatitis CJPRN-UMIN000001067Japanese Consortium for the Study of Liver Diseases270
进行中（未招募）
1 期
clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression.Infection with human immunodeficiency virus (HIV).MedDRA version: 20.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2015-000274-35-ESFUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA265
未知
3 期
Phase III Long term Study of KRP-AB1102F DPICOPDJPRN-jRCT2080222177Kyorin Pharmaceutical Co.,LTD130
已完成
1 期
A clinical study to see the effect of an Ayurvedic formulation in comparison with Olopatadine (0.1%) Eye Drop in allergic conjunctivitisCTRI/2019/03/018185Sane Guruji Arogya Kendra